Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $16.3 million.

  • Ligand Pharmaceuticals' Change in Receivables rose 44026.71% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 134032.34%. This contributed to the annual value of $6.5 million for FY2024, which is 14832.76% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Change in Receivables is $16.3 million, which was up 44026.71% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Change in Receivables ranged from a high of $20.4 million in Q2 2022 and a low of -$43.6 million during Q1 2022
  • Its 5-year average for Change in Receivables is $105631.6, with a median of $2.7 million in 2022.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Change in Receivables crashed by 170995.44% in 2022 and then soared by 75715.32% in 2024.
  • Ligand Pharmaceuticals' Change in Receivables (Quarter) stood at $19.8 million in 2021, then crashed by 275.8% to -$34.8 million in 2022, then skyrocketed by 91.85% to -$2.8 million in 2023, then surged by 299.82% to $5.7 million in 2024, then skyrocketed by 187.89% to $16.3 million in 2025.
  • Its Change in Receivables was $16.3 million in Q3 2025, compared to $2.8 million in Q2 2025 and $576000.0 in Q1 2025.